Advertisement

Picture Berlin Partner BIO 2024 International Convention San Diego 650x100px

Deals > All

Find below collaborations, license and distribution agreements, grants, investments and loan agreements in France and Monaco or involving organisations from these countries.

Total search results: 1956 | Ordered by Date (descending)
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page

order ascendingorder descendingDeal: Collaboration or Financing order ascendingorder descendingDate
GSK–BioVersys: alpibectir, 202405– collab expansion to speed up development to treat tuberculosis 2024-05-07
Memo Therapeutics–Eurazeo: investment, 202405 financing round Series C extension totalling CHF20m incl new investor Kurma Partners 2024-05-07
Memo Therapeutics–SEVERAL: investment, 202405 financing round Series C extension CHF20m bringing total Series C to CHF45m 2024-05-07
Cultimate Foods–Big Idea Ventures: investment, 202404 seed financing round totalling €2.3m incl co-investor Big Idea Ventures 2024-04-23
Cultimate Foods–SEVERAL: investment, 202404 seed financing round €2.3m led by HTGF 2024-04-23
Prothea Technologies–Mérieux: investment, 202404 financing round Series A totalling €12m incl co-lead investor Mérieux Equity Partners 2024-04-09
Prothea Technologies–SEVERAL: investment, 202404 financing round Series A €12m co-led by Earlybird + Mérieux Equity Partners 2024-04-09
SurgeCare–50 Partners Santé: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor 50 Partners Santé 2024-03-27
SurgeCare–Boutique Venture: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor Boutique Venture 2024-03-27
SurgeCare–Eurazeo: investment, 202403 2nd financing round totalling €7.5m incl lead investor Eurazeo 2024-03-27
SurgeCare–France (govt): grant, 202403c BPI grants incl support for deep tech development + Future Investment Program 2024-03-27
SurgeCare–HCVC: investment, 202403 2nd financing round totalling €7.5m incl existing + co-investor HCVC 2024-03-27
SurgeCare–Kima: investment, 202403 2nd financing round totalling €7.5m incl co-investor Kima 2024-03-27
SurgeCare–MH Innov’: investment, 202403 2nd financing round totalling €7.5m incl co-investor MH Innov’ 2024-03-27
SurgeCare–SEVERAL: investment, 202403 2nd financing round €7.5m led by Eurazeo 2024-03-27
SurgeCare–Teampact Ventures: investment, 202403 2nd financing round totalling €7.5m incl co-investor Teampact 2024-03-27
Kranus Health–Anaxago: investment, 202403 financing round Series A expansion totalling $5m incl new investor CapHorn 2024-03-25
Kranus Health–Future Positive Capital: investment, 202403 financing round Series A expansion totalling $5m incl new investor Future Positive Capital 2024-03-25
Kranus Health–SEVERAL: investment, 202403 financing round Series A expansion $5m bringing total Series A to $20m 2024-03-25
Mirador Therapeutics–Sanofi: investment, 202403 Mirador emerges with total of >$400m in financing incl investor Sanofi Ventures 2024-03-21
Mirador Therapeutics–SEVERAL: investment, 202403 emerges with >$400m in financing led by ARCH Venture with early investments by OrbiMed + Fairmount 2024-03-21
Sanofi–Owkin: AI-based drug development, 202403– collab expansion into using AI for drug positioning in immunology 2024-03-21
Cure51–Hitachi: investment, 202403 seed financing round totalling €15m incl co-investor Hitachi Ventures GmbH 2024-03-20
Cure51–Life Extension Ventures: investment, 202403 seed financing round totalling €15m incl co-investor Life Extension Ventures 2024-03-20
Cure51–PERSON: investment, 202403 seed financing round totalling €15m incl co-investors Xavier Niel + Olivier Pomel 2024-03-20
Cure51–SEVERAL: investment, 202403 seed financing round €15m led by Sofinnova Partners 2024-03-20
Cure51–Sofinnova: investment, 202403 seed financing round totalling €15m incl lead investor Sofinnova Partners 2024-03-20
Amolyt Pharma–AstraZeneca: investment, 202403– acquisition $800m upfront cash + $250m milestones 2024-03-14
Tubulis–Andera Partners: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Andera Partners 2024-03-14
Tubulis–BPCE: investment, 202403 financing round Series B2 totalling €128m incl existing + co-investor Seventure Partners 2024-03-14
Tubulis–SEVERAL: investment, 202403 financing round Series B2 €128m led by EQT Life Sciences + Nextech Invest 2024-03-14
Inpart–Norstella: business services, 202409– collab integrating Evaluate data into Deal CRM of Inpart 2024-02-29
Stilla Technologies–SEVERAL: investment, 202402 financing round Series C $26.5m led by CLIIF 2024-02-22
AZmed–Maison Worms: investment, 202402 financing round Series A totalling €15m incl investor Maison Worms 2024-02-20
AZmed–SEVERAL: investment, 202402 financing round Series A €15m 2024-02-20
AZmed–Teampact Ventures: investment, 202402 financing round Series A totalling €15m incl investor Teampact Ventures 2024-02-20
AZmed–Techstars: investment, 202402 financing round Series A totalling €15m incl investor Techstars 2024-02-20
Bioptimus–SEVERAL: investment, 202402 company emerges with seed financing round $35m led by Sofinnova Partners 2024-02-20
Sensorion–Aquilo Capital: investment, 202402 reserved offering totalling €50.5m incl new investor Aquilo Capital 2024-02-09
Sensorion–Invus Group: investment, 202402 reserved offering totalling €50.5m incl existing investor Invus Group 2024-02-09
Sensorion–Redmile Group: investment, 202402 reserved offering totalling €50.5m incl existing investor Redmile Group 2024-02-09
Sensorion–SEVERAL: investment, 202402 reserved offering €50.5m with 88.6m new ordinary shares at €0.57/share to existing + new investors 2024-02-09
Sensorion–Sofinnova: investment, 202402 reserved offering totalling €50.5m incl existing investor Sofinnova Partners 2024-02-09
GenSight Biologics–Heights Capital: investment, 202402 capital increase totalling €5m incl €0.25m from new investor CVI Investmens Inc 2024-02-08
GenSight Biologics–Invus Group: investment, 202402 capital increase totalling €5m incl €1.75m from existing investor Invus Public Equities LP 2024-02-08
GenSight Biologics–SEVERAL: investment, 202402 capital increase €5m (€4.7m net) with 13.1m new shares at €0.38/share 2024-02-08
GenSight Biologics–Sofinnova: investment, 202402 capital increase totalling €5m incl €2m from existing investor Sofinnova Crossover I SLP 2024-02-08
GenSight Biologics–Univ Pittsburgh: investment, 202402 capital increase totalling €5m incl existing investor UPMC Enterprises 2024-02-08
Sensorion–Institut Pasteur: gene therapy, 202401–202812 collab framework agreem extension incl license options for gene therapies for ear diseases 2024-02-05
Aqemia–Elaia Partners: investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Elaia 2024-01-30
Aqemia–Eurazeo: investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Eurazeo 2024-01-30
Aqemia–France (govt): investment, 202401 financing round Series A extension totalling €30m incl existing + co-investor Bpifrance Large Venture 2024-01-30
Aqemia–SEVERAL: investment, 202401 financing round Series A extension €30m led by Wendel Growth bringing total Series A to €60m 2024-01-30
Aqemia–Wendel: investment, 202401 financing round Series A extension totalling €30m incl new + lead investor Wendel Growth 2024-01-30
Rhineland-Palatinate (govt)–Axa: business park management, 202401– collab of Kadans Science Partner Deutschland + Technologiezentrum Mainz for biotech 2024-01-29
Affluent Medical–SEVERAL: investment, 2021401 bridge financing €3.5m with 2.24m new ordinary shares at €1.56/share from existing key shareholders 2024-01-26
Disco Pharmaceuticals–Sofinnova: investment, 202401 seed financing round totalling €20m incl lead investor Sofinnova Partners 2024-01-16
GlycoEra–BMS: investment, 202401 financing round Series A extension with new investor BMS 2024-01-05
HI-Bio–Jeito Capital: investment, 202401 financing round Series B totalling $95m incl existing + co-investor Jeito Capital 2024-01-04
HI-Bio–SEVERAL: investment, 202401 financing round Series B $95m led by new investor Alpha Wave Global 2024-01-04
Caresyntax–MTIP: investment, 2023 financing round incl $15m from MTIP II Fund 2023-12-31
Caresyntax–SEVERAL: investment, 2023 financing round with MTIP II + BlackRock + PFM Health Scienes et al 2023-12-31
Planet A Foods–Omnes Capital: investment, 202312c financing round Series A totalling €15.4m incl co-investor Omnes Capital 2023-12-31
Planet A Foods–SEVERAL: investment, 202312c financing round Series A €15.4m led by World Fund 2023-12-31
Elitech–Bruker: investment, 202312– acquisition €870m in cash of Elitech Group from PAI Partners SIGNED Put Option Letter 2023-12-23
Brinter–UPM: bioink, 202312– distribution of GrowInk bioinks of UPM Biomedicals by Brinter in North America + most of Europe + AU+NZ 2023-12-21
Sofinnova–Gustave Roussy: oncology startup acceleration in France, 202312– collab strategic alliance Sofinnova Biovelocita + Gustave Roussy Transfert 2023-12-13
Antabio–SEVERAL: investment, 202312 financing round Series B €25m with AMR Action Fund + EIC Fund plus existing investors 2023-12-12
Freya Biosciences–SEVERAL: investment, 202312 financing round Series A $38m led by Sofinnova Partners + OMX Ventures 2023-12-12
Freya Biosciences–Sofinnova: investment, 202312 financing round Series A totalling $38m incl co-lead investor Sofinnova Partners 2023-12-12
Eligo Bioscience–BPCE: investment, 202312 financing round Series B totalling $30m incl existing + co-investor Seventure Partners HFL 2023-12-05
Eligo Bioscience–France (govt): investment, 202312 financing round Series B totalling $30m incl new + co-investor Bpifrance InnoBio 2 Fund 2023-12-05
Eligo Bioscience–Khosla Ventures: investment, 202312 financing round Series B totalling $30m incl existing + co-investor Khosla Ventures 2023-12-05
Eligo Bioscience–Sanofi: investment, 202312 financing round Series B totalling $30m incl new + lead investor Sanofi Ventures 2023-12-05
Eligo Bioscience–SEVERAL: investment, 202312 financing round Series B $30m led by Sanofi Ventures 2023-12-05
Sanofi–Aqemia: drug discovery, 202312– collab multi-year collab up to $140m using Deep Physics platform with AI for small moledule discovery 2023-12-05
GenSight Biologics–SEVERAL: investment, 202311 private + public offerings totalling €4.7m 2023-11-21
RED Horticulture–Demeter: investment, 202311 financing round Series A totalling €17m incl existing investor Demeter IM 2023-11-21
RED Horticulture–ECBF: investment, 202311 financing round Series A totalling €17m incl new + lead investor ECBF 2023-11-21
RED Horticulture–SEVERAL: investment, 202311 financing round Series A €17m led by ECBF with Demeter IM + Unigrains 2023-11-21
RED Horticulture–Unigrains: investment, 202311 financing round Series A totalling €17m incl new investor Unigrains 2023-11-21
NMD Pharma–SEVERAL: investment, 202311 financing round Series B €75m led by existing investor Jeito Capital 2023-11-15
T-Therapeutics–SEVERAL: investment, 202311 financing round Series A £48m 2023-11-15
Nouscom–Andera Partners: investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Andera Partners 2023-11-14
Nouscom–France (govt): investment, 202311 financing round Series C totalling €67.5m incl new + co-lead investor Bpifrance InnoBio 2 Fund 2023-11-14
Nouscom–SEVERAL: investment, 202311 financing round Series C €67.5m led by Andera Partners + Bpifrance InnoBio 2 Fund + M Ventures 2023-11-14
LimFlow–Inari Medical: investment, 202311– acquisition $250m cash upfront at closing + $165m by Inari Medical 2023-11-01
MeiraGTx–Sanofi: investment, 202310 strategic investment $30m with 4m ordinary shares at $7.5/share incl right of first negotation for some assets 2023-10-30
Global Bioenergies–L’Oréal: investment, 202310 existent L’Oréal is largest shareholder with a 13.5% stake 2023-10-19
Global Bioenergies–NewCap: public relations, 202310 service existent by NewCap 2023-10-19
Oxford Nanopore–Mérieux: investment, 202310 investment £69.1m purchase of 29m ordinary shares at £2.38/share by bioMérieux 2023-10-19
Mablink Bioscience–Lilly: investment, 202310 acquisition of Mablink Bioscience by Eli Lilly 2023-10-18
Servier–Owkin: AI-based drug discovery, 202310– collab using AI for RnD of precision therapeutics for cancer + other indications 2023-10-17
LimmaTech Biologics–SEVERAL: investment, 202310 financing round Series A $37m co-led by Adjuvant Capital + AXA IM Alts + Novo REPAIR Impact Fund 2023-10-09
Global Bioenergies–France (govt): credit, 202310– repayable advance €6.56m for construction of biosourced isobutene plant in France 2023-10-04
Global Bioenergies–France (govt): grant, 202310– subsidy €9.84m for construction of biosourced isobutene plant in France 2023-10-04
Orakl Oncology–SEVERAL: investment, 202310 financing round €3m led by Speedinvest with HCVC + Verve Ventures 2023-10-04
Kranus Health–A Round Capital: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor A Round 2023-10-02
Kranus Health–CSS (CH): investment, 202310 financing round Series A expansion totalling approx $8.5m incl new + co-lead investor SwissHealth Ventures 2023-10-02
Kranus Health–High-Tech Gründerfonds: investment, 202310 financing round Series A expansion totalling approx $8.5m incl existing + co-investor HTGF 2023-10-02
1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20  next pagenext page



Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x200px

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to info@iito.de and simply fill the subject line with the word »LSE Newsletter«

Find more infos about advertising at [iito] web portals in our media flyer [iito] in a Nutshell [PDF file]

Please visit also our web portals for the life sciences in German-speaking Europe (DE, AT & CH) and the worldwide mass spectrometry industry at Life-Sciences-Germany.com (life sciences in German-speaking Europe) and Mass-Spec-Capital.com (worldwide mass spectrometry)


Advertisement

Picture Berlin Partner Top News Healthtech Company Mika 650x300px

» top